- Home
- VNDA vs HYLN Comparison
VNDA vs HYLN Comparison
Compare VNDA & HYLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- HYLN
- Stock Information
- Founded
- VNDA 2002
- HYLN 2018
- Country
- VNDA United States
- HYLN United States
- Employees
- VNDA N/A
- HYLN N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- HYLN Construction/Ag Equipment/Trucks
- Sector
- VNDA Health Care
- HYLN Consumer Discretionary
- Exchange
- VNDA Nasdaq
- HYLN Nasdaq
- Market Cap
- VNDA 289.0M
- HYLN 299.2M
- IPO Year
- VNDA 2006
- HYLN N/A
- Fundamental
- Price
- VNDA $5.28
- HYLN $1.87
- Analyst Decision
- VNDA Strong Buy
- HYLN Strong Buy
- Analyst Count
- VNDA 3
- HYLN 1
- Target Price
- VNDA $14.00
- HYLN $5.00
- AVG Volume (30 Days)
- VNDA 993.5K
- HYLN 1.6M
- Earning Date
- VNDA 10-29-2025
- HYLN 11-11-2025
- Dividend Yield
- VNDA N/A
- HYLN N/A
- EPS Growth
- VNDA N/A
- HYLN N/A
- EPS
- VNDA N/A
- HYLN N/A
- Revenue
- VNDA $212,074,000.00
- HYLN $4,272,000.00
- Revenue This Year
- VNDA $14.32
- HYLN $261.63
- Revenue Next Year
- VNDA $37.05
- HYLN $219.63
- P/E Ratio
- VNDA N/A
- HYLN N/A
- Revenue Growth
- VNDA 11.12
- HYLN 124.55
- 52 Week Low
- VNDA $3.81
- HYLN $1.11
- 52 Week High
- VNDA $5.70
- HYLN $3.97
- Technical
- Relative Strength Index (RSI)
- VNDA 60.60
- HYLN 47.70
- Support Level
- VNDA $4.72
- HYLN $1.56
- Resistance Level
- VNDA $5.46
- HYLN $1.80
- Average True Range (ATR)
- VNDA 0.24
- HYLN 0.16
- MACD
- VNDA 0.09
- HYLN -0.00
- Stochastic Oscillator
- VNDA 86.13
- HYLN 47.65
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About HYLN Hyliion Holdings Corp.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.